Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179307 | 0.95 | ALOX15 (0.42) | ALOX15GNAO1HTR4MAPTGSK3B | |
| SCHEMBL5178776 | 0.83 | CHRM1 (0.36) | SIGMAR1GNAO1GNAI3GNAI1 | |
| SCHEMBL5177566 | 0.81 | KEAP1 (0.39) | SIGMAR1GNAO1GNAI3GNAI1 | |
| SCHEMBL5177836 | 0.79 | ALOX15 (0.39) | ALOX15GNAO1MAPTGNAI3GNAI1 | |
| SCHEMBL5178698 | 0.77 | PRMT3 (0.42) | ALOX15GNAO1GNAI3GNAI1 | |
| SCHEMBL11477493 | 0.76 | GNAO1 (0.54) | GNAO1KCNH2GNAI3GNAI1 | |
| SCHEMBL5179458 | 0.74 | ALOX15 (0.43) | ALOX15HTR4MAPTHTR7 | |
| SCHEMBL27395113 | 0.74 | GNAO1 (0.37) | ALOX15SIGMAR1GNAO1KCNH2 | |
| SCHEMBL27416761 | 0.74 | ALOX15 (0.36) | ALOX15SIGMAR1GNAO1KCNH2HTR7 | |
| SCHEMBL11472846 | 0.73 | GNAO1 (0.51) | GNAO1KCNH2GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927174-B1 | NEW AMINO ALCOHOL DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND MEDICAMENTS AND REAGENTS CONTAINING THESE COMPOUNDS | MEDIGENE AG (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-7097854-B2 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | MEDIGENE ONCOLOGY GMBH (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20030236266-A1 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | ROCHE DIAGNOSTICS GMBH | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236266-A1 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | ADH1C, ADH1A, ADH5 | ALOX15 1312/4885SIGMAR1 126/4885GNAO1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.